CRESCENT BIOPHARMA, INC. — Director's Dealing 2017

Jan 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2017-01-04

Reporting Person: Thackray Helen M. (SVP Clinical Development, CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-04	Employee Stock Option (right to buy)	$6.33	A	75000	Acquired	2027-01-03	Common Stock (75000)	Direct

Footnotes

F1: One-fourth of the shares underlying this option vest on January 4, 2018 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.